Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Commences Offer for Orchid Shares

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that it has launched its cash tender offer to acquire all of the outstanding common shares of Orchid Cellmark.

The firms signed the merger agreement earlier this month, under which LabCorp will pay $2.80 per share to acquire all outstanding shares of Orchid including options. The total value of the deal is around $85.4 million.

The companies said the deal strengthens LabCorp's presence and brand name in identity testing in the US and establishes a presence in identity testing in the UK.

Orchid Cellmark's board has approved the agreement and plan of merger and has recommended that shareholders vote in favor of the acquisition.

The tender offer is scheduled to expire at 5:00 p.m., New York City time, on May 17, unless it is extended.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.